Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

T
PII-221
TETRAVALENCY IMPACT ON BISPECIFIC ANTIBODY-ACHIEVED RECEPTOR OCCUPANCY AND TARGET DOWNREGULATION: ESTIMATION BY TRANSLATIONAL PK/RO MODEL OF CTX8371 ANTIBODY

Favorite
PII-069
THE ANTI-OSTEOCLASTIC EFFECTS AND BONE-AFFINITY PROPERTIES OF GERANYLGERANYL DIPHOSPHATE SYNTHASE INHIBITOR RAM2061

Favorite
PII-193
THE CONTENTS OF IMMUNOGENICITY ASSESSMENT DURING THE REVIEW PROCESS OF NEW DRUG APPLICATION IN JAPAN

Favorite
PT-012
THE EFFECT OF BUPRENORPHINE VERSUS METHADONE TREATMENT ON NEUROCOGNITIVE IMPAIRMENT IN PERSONS WITH HIV AND OPIOID USE DISORDER.

Favorite
PII-157
THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS (PK) OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, IN HEALTHY ADULT PARTICIPANTS.

Favorite
PII-158
THE EFFECT OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, ON DABIGATRAN PHARMACOKINETICS (PK) IN HEALTHY ADULT PARTICIPANTS.

Favorite
PII-034
THE FEASIBILITY OF PHARMACOKINETIC-GUIDED HYDROXYUREA DOSING FOR CHILDREN WITH SICKLE CELL ANEMIA IN UGANDA: ANALYSIS OF THE ALTERNATIVE DOSING AND PREVENTION OF TRANSFUSIONS (ADAPT) TRIAL.

Favorite
PII-040
THE IMPACT OF HIV-1 TAT AND MORPHINE ON SPATIAL DISTRIBUTION OF DRUGS IN THE BRAIN.

Favorite
PII-159
THE NEED FOR EQUITABLE REPRESENTATION IN PHARMACOKINETIC STUDIES TO ENHANCE OPTIMAL DOSING STRATEGIES TO TREAT POVERTY-RELATED DISEASES IN MALNOURISHED CHILDREN.

Favorite
LB-034
THE POPULATION PHARMACOKINETICS STUDY OF ANTI-TUMOR B AMONG HEALTHY VOLUNTEER AND ORAL CANCER PATIENTS TO INFORM DOSE DECISION

Favorite
PII-184
TOWARDS ASSISTING POTENTIAL PREVENTION CLINICAL TRIALS OF BONE-PROTECTIVE THERAPIES FOR DUCHENNE MUSCULAR DYSTROPHY USING DEEP SEGMENTED IMAGING BIOMARKER

Favorite
LB-035
TOWARDS MORE ROBUST EVALUATION OF THE PREDICTIVE PERFORMANCE OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS: USING CONFIDENCE INTERVALS TO SUPPORT USE OF MODEL-INFORMED DOSING IN CLINICAL CARE

Favorite
PII-070
TUCATINIB DOES NOT INCREASE PACLITAXEL PLASMA CONCENTRATIONS IN PATIENTS WITH HER2+ GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Favorite